Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998545 | 1.00 | TP53 (0.32) | TP53GPR119TDP1HRH3 | |
| SCHEMBL344785 | 1.00 | TP53 (0.32) | TP53GPR119TDP1HRH3 | |
| SCHEMBL5991039 | 0.95 | HRH3 (0.33) | HRH3 | |
| SCHEMBL4744840 | 0.90 | TAAR1 (0.34) | — | |
| SCHEMBL642149 | 0.90 | TAAR1 (0.34) | — | |
| SCHEMBL5120488 | 0.90 | TAAR1 (0.34) | — | |
| SCHEMBL559976 | 0.89 | HRH3 (0.34) | TP53GPR119TDP1HRH3 | |
| SCHEMBL9937310 | 0.88 | DPP4 (0.33) | HRH3 | |
| SCHEMBL5667133 | 0.87 | TAAR1 (0.36) | HRH3 | |
| SCHEMBL24174014 | 0.86 | PDE4B (0.35) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151638-A2 | COMPOUNDS FOR FGFRS INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4373814-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024057021-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| WO-2023240138-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2023235456-A1 | PENEM ANTIBACTERIALS AGAINST MYCOBACTERIAL PATHOGENS AND D,D- AND L,D TRANSPEPTIDASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-112707893-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-6417203-B1 | HETEROCYCLIC AMIDES | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| EP-1138672-A1 | Process for the preparation of 3-amino-pyrrolidine derivatives | Basilea Pharmaceutica AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| US-6180627-B1 | INDOLE, INDAZOLE, BENZOTRIAZOLE AND BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| EP-0997474-A1 | Antithrombotic agents | PFIZER INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5977381-A | Process for making 3-amino-pyrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0928787-A1 | Process for the preparation of 3-amino-pyrrolidine derivatives | F. Hoffmann-La Roche AG (CH) | 1999-07-14 | — | — | EP | disclosed |
| EP-0394685-A2 | (S)-7-(3-Amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid | WARNER-LAMBERT COMPANY (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4916141-A | ANTIBACTERIAL | WARNER-LAMBERT COMPANY (US) | 1990-04-10 | — | — | US | disclosed |
| US-4851418-A | Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0304087-A2 | Quinolone and naphthyridine antibacterial agents containing an alpha-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | TP53 1704/4885GPR119 978/4885TDP1 1426/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TP53 1474/4885GPR119 2426/4885TDP1 236/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TP53 1474/4885GPR119 2426/4885TDP1 236/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TP53 1474/4885GPR119 2426/4885TDP1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.